OFS
NBIX icon

OneAscent Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

OneAscent Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$210K Buy
+2,157
New +$226K 0.21% 131
2020
Q4 		– Sell
-2,676
Closed -$257K – 163
2020
Q3 		$257K Buy
2,676
+392
+17% +$45.3K 0.13% 152
2020
Q2 		$279K Buy
+2,284
New +$252K 0.19% 124

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

OneAscent Financial Services's NBIX Position: Q1 2021 in Review

OneAscent Financial Services opened a new position in Neurocrine Biosciences (NBIX) in Q1 2021: 2,157 shares worth $210K. The stake represents 0.21% of the portfolio and ranks #131 among its holdings. This is a return to the name: OneAscent Financial Services previously reported a position in NBIX as recently as Q3 2020.

OneAscent Financial Services first reported a position in NBIX in Q2 2020 and has held it in 3 quarters since. The position peaked at $279K in Q2 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • OneAscent Financial Services held 2,157 shares of Neurocrine Biosciences worth $210K as of Q1 2021.
  • Neurocrine Biosciences was a new OneAscent Financial Services position in Q1 2021.
  • Neurocrine Biosciences made up 0.21% of OneAscent Financial Services's portfolio in Q1 2021, its #131 holding.
  • OneAscent Financial Services first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 3 quarters since.
  • OneAscent Financial Services's Neurocrine Biosciences position peaked at $279K in Q2 2020.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on OneAscent Financial Services's 13F filing for Q1 2021, filed 27 Apr 2021.